— Know what they know.
Not Investment Advice

VICP OTC

Vicapsys Life Sciences, Inc.
1W: -17.2% 1M: -35.0% 3M: -55.5% YTD: -56.7% 1Y: -63.3% 3Y: +160.0% 5Y: +73.3%
$0.65
+0.14 (+27.45%)
 
Weekly Expected Move ±47.6%
$0 $0 $1 $1 $1
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 38 · $21.0M mcap · 18M float · 0.0024% daily turnover · Short 81% of daily vol

Balance Sheet Trends

Total Assets
$12K -70.7% ▼
5Y CAGR: -55.9%
Total Liabilities
$3M +47.1% ▲
5Y CAGR: +48.8%
Shareholders Equity
-$3M -49.5% ▼
Cash & Investments
$12K +23.1% ▲
5Y CAGR: -46.5%
Total Debt
$579K +63.6% ▲
Net Debt
$567K +64.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$1K$217K$14K$9K$12K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$1K$217K$14K$9K$12K
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$50K$0$0
Total Current Assets$1K$223K$72K$40K$12K
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$403K$372K$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$50K$0$0
Total Non-Current Assets$403K$372K$50K$0$0
Total Assets$404K$594K$72K$40K$12K
— Liabilities —
Accounts Payable$508K$488K$635K$1M$2M
Short-Term Debt$0$0$0$354K$579K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$230K$0$0$0$0
Total Current Liabilities$853K$716K$1M$2M$3M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$738K$0$908K$0$0
Total Liabilities$853K$716K$1M$2M$3M
— Equity —
Common Stock$17K$20K$31K$32K$32K
Retained Earnings-$14M-$14M-$15M-$16M-$17M
Accumulated OCI$651$12K$727$0$0
Total Stockholders Equity-$449K-$122K-$951K-$2M-$3M
Total Liabilities & Equity$404K$594K$72K$40K$12K
— Key Metrics —
Total Debt$0$0$0$354K$579K
Net Debt-$1K-$217K-$14K$344K$567K
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms